DiaMedica Therapeutics In... (DMAC)
DiaMedica Therapeutics Statistics
Share Statistics
DiaMedica Therapeutics has 42.86M shares outstanding. The number of shares has increased by 12.89% in one year.
| Shares Outstanding | 42.86M |
| Shares Change (YoY) | 12.89% |
| Shares Change (QoQ) | 0.22% |
| Owned by Institutions (%) | 15.74% |
| Shares Floating | 24.06M |
| Failed to Deliver (FTD) Shares | 87 |
| FTD / Avg. Volume | 0.1% |
Short Selling Information
The latest short interest is 175.55K, so 0.41% of the outstanding shares have been sold short.
| Short Interest | 175.55K |
| Short % of Shares Out | 0.41% |
| Short % of Float | 0.73% |
| Short Ratio (days to cover) | 3.88 |
Valuation Ratios
The PE ratio is -8.98 and the forward PE ratio is -7.53. DiaMedica Therapeutics's PEG ratio is 0.
| PE Ratio | -8.98 |
| Forward PE | -7.53 |
| PS Ratio | 0 |
| Forward PS | 1.9 |
| PB Ratio | 5.39 |
| P/FCF Ratio | -9.93 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for DiaMedica Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.28, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.28 |
| Quick Ratio | 8.28 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | - |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-905.33K |
| Employee Count | 27 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -30K |
| Effective Tax Rate | 0.12% |
Stock Price Statistics
The stock price has increased by 37.4% in the last 52 weeks. The beta is 1.49, so DiaMedica Therapeutics's price volatility has been higher than the market average.
| Beta | 1.49 |
| 52-Week Price Change | 37.4% |
| 50-Day Moving Average | 5.4 |
| 200-Day Moving Average | 4.61 |
| Relative Strength Index (RSI) | 29.92 |
| Average Volume (20 Days) | 90.5K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | 0 |
| Net Income | -24.44M |
| EBITDA | 0 |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.6 |
Balance Sheet
The company has 3.02M in cash and 340K in debt, giving a net cash position of 2.69M.
| Cash & Cash Equivalents | 3.02M |
| Total Debt | 340K |
| Net Cash | 2.69M |
| Retained Earnings | -140M |
| Total Assets | 46.34M |
| Working Capital | 39.22M |
Cash Flow
In the last 12 months, operating cash flow was -22.08M and capital expenditures -25K, giving a free cash flow of -22.1M.
| Operating Cash Flow | -22.08M |
| Capital Expenditures | -25K |
| Free Cash Flow | -22.1M |
| FCF Per Share | -0.55 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DMAC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for DMAC is $8, which is 129.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $8 |
| Price Target Difference | 129.2% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Nov 15, 2018. It was a backward split with a ratio of 1:20.
| Last Split Date | Nov 15, 2018 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | 10.33 |
| Piotroski F-Score | 2 |